Sign In
Buy DRMA
$1.27
-0.0900 (-6.62%)
At Close: Jun 03, 2026
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
04:05pm, Thursday, 21'st Mar 2024
- Initiated enrollment of DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial in Q4 2023 - - Raised $9.1 million in gross proceeds from three financings completed in 2023 - - R
Dermata to Present at the Emerging Growth Conference on February 7, 2024
09:00am, Thursday, 01'st Feb 2024
- Company to provide a corporate overview followed by a live question and answer session - SAN DIEGO, CA / ACCESSWIRE / February 1, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Derm
Why Is Dermata Therapeutics (DRMA) Stock Up 62% Today?
08:31am, Friday, 05'th Jan 2024
Dermata Therapeutics (NASDAQ: DRMA ) stock is soaring higher on Friday after the clinical-stage medical dermatology company announced a new patent in Japan. This new patent covers DMT410 for the tre
Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
04:05pm, Thursday, 04'th Jan 2024
- This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company is currently discussing partnership opport
Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
04:05pm, Wednesday, 20'th Dec 2023
- About 550 patients will be treated once weekly for 12 weeks - - STAR-1 topline results expected in first quarter of 2025 - - Acne affects about 50 million patients in the U.S. - SAN DIEGO, CA / ACCE
Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug
10:31am, Friday, 17'th Nov 2023
Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
01:30pm, Thursday, 16'th Nov 2023
SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment o
- DMT310 Phase 3 STAR-1 (Spongilla Treatment of Acne Research) clinical trial will evaluate the efficacy and safety of once-weekly treatments of DMT310 for 12 weeks in moderate-to-severe acne patients
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
04:05pm, Thursday, 09'th Nov 2023
- Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 - - Received positive feedback from FDA on its End of Phase 2 meeting package in June 2023 - - Complete
Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial
09:00am, Thursday, 26'th Oct 2023
- Dermata is prepared to initiate DMT310 Phase 3 STAR-1 clinical trial by the end of 2023 - - Investigational sites have been selected - - Clinical trial materials are ready to be shipped to investiga
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
04:15pm, Thursday, 10'th Aug 2023
- Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 - - Received positive feedback on its End of Phase 2 meeting package from FDA in June 2023 - - Phase 3
SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical a
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate
01:43pm, Friday, 21'st Apr 2023
Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne.
Why Is Dermata Therapeutics (DRMA) Stock Up 22% Today?
08:49am, Thursday, 20'th Apr 2023
Dermata Therapeutics (NASDAQ: DRMA ) stock is on the rise Thursday following an update concerning its moderate-to-severe acne treatment. The big news here is the FDA signed off on the company's abilit
Why Is Dermata Therapeutics (DRMA) Stock Up 23% Today?
08:14am, Friday, 24'th Mar 2023
Dermata Therapeutics (NASDAQ: DRMA ) stock is taking off on Friday despite a lack of news from the clinical-stage biotechnology company. While there are no press releases or filings that explain why D
